MILANAPHARM

MilanaPharm is a privately held specialty pharmaceutical company built upon a proprietary drug delivery platform capable of delivering a large number of active compounds. The platform, TRI-726, can deliver actives from several hours to several days. MilanaPharm’s focus is on developing pharmaceutical products within the chronic wound management segment. We strive to improve patient quality of life and reduce opioid dependence and addiction with effective alternatives for healing and pain.

#SimilarOrganizations #People #Website #More

MILANAPHARM

Industry:
Life Science Pharmaceutical

Founded:
2010-01-01

Address:
Tallassee, Alabama, United States

Country:
United States

Website Url:
http://www.milanapharm.com

Status:
Active

Contact:
(334) 315-8981

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome


Similar Organizations

quadriga-biosciences-logo

Quadriga BioSciences

Quadriga BioSciences is a pharmaceutical company developing proprietary targeted cancer therapies.

scitech-development-logo

SciTech Development

Specialty pharmaceutical company dedicated to advancing cancer treatment with a revolutionary new Drug Delivery Platform (SDP)

Current Employees Featured

not_available_image

James A. H. Harwick
James A. H. Harwick Chief Executive Officer @ MilanaPharm
Chief Executive Officer
2010-01-01

Official Site Inspections

http://www.milanapharm.com

  • Host name: 118.172.69.216.host.secureserver.net
  • IP address: 216.69.172.118
  • Location: Scottsdale United States
  • Latitude: 33.6013
  • Longitude: -111.8867
  • Metro Code: 753
  • Timezone: America/Phoenix
  • Postal: 85260

Loading ...

More informations about "MilanaPharm"

MilanaPharm - Crunchbase Company Profile & Funding

MilanaPharm is a privately held specialty pharmaceutical company built upon a proprietary drug delivery platform capable of delivering a large number of active compounds. The platform, TRI …See details»

MilanaPharm Company Profile 2024: Valuation, Funding

Developer of a drug delivery platform intended for non-opioid pain relief, wound management and infection control. The company utilizes a combination of a tri-block copolymer and a natural …See details»

MilanaPharm - LinkedIn

Innovative product development to improve quality of life. | Pharmaceutical research and development focusing on non-opioid pain relief, wound management and infection control.See details»

MilanaPharm - Overview, News & Similar companies - ZoomInfo

May 9, 2019 · View MilanaPharm (www.milanapharm.com) location in Alabama, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»

MilanaPharm - Products, Competitors, Financials, Employees ...

MilanaPharm is a pharmaceutical company focused on innovative product development to improve quality of life, particularly in the domains of pain relief, wound management, and …See details»

MilanaPharm - Company Profile - Tracxn

Oct 26, 2024 · MilanaPharm - Hydro-gel based proprietary drug delivery platform for treating chronic wounds. Raised a total funding of $195K over 2 rounds. MilanaPharm has 2963 …See details»

MilanaPharm LLC - Drug pipelines, Patents, Clinical trials - Synapse

Explore MilanaPharm LLC with its drug pipeline, therapeutic area, technology platform, .See details»

MilanaPharm - Contacts, Employees, Board Members, Advisors

MilanaPharm has 1 current employee profile, Chief Executive Officer James A. H. Harwick. MilanaPharm is a privately held specialty pharmaceutical company built upon a proprietary …See details»

MilanaPharm - Crunchbase

MilanaPharm is a privately held specialty pharmaceutical company built upon a proprietary drug delivery platform.See details»

Press Release Distribution and Management - GlobeNewswire

TALLASSEE, Ala., May 09, 2019 (GLOBE NEWSWIRE) -- MilanaPharm, a specialty pharmaceutical company focused on the development of innovative, non-opioid …See details»

Hammock Pharmaceuticals Announces the Licensing of Women's …

CHARLOTTE, N.C., Jan. 9, 2017 /PRNewswire/ -- Hammock Pharmaceuticals, Inc. today announced the execution of a license agreement with MilanaPharm/TriLogic Pharma for the …See details»

MilanaPharm Receives Notice of Allowance from U.S. Patent

TALLASSEE, Ala., May 09, 2019 (GLOBE NEWSWIRE) -- MilanaPharm, a specialty pharmaceutical company focused on the development of innovative, non-opioid …See details»

Hammock Pharmaceuticals Announces Licensing Sale and Global …

Charlotte | December 6, 2018 – Hammock Pharmaceuticals Inc., TriLogic Pharma LLC and MilanaPharm LLC announced today that it has entered into a definitive agreement with Daré …See details»

Hammock Pharmaceuticals Announces The Licensing Of Women's …

MilanaPharm is a specialty pharmaceutical company built upon a proprietary drug delivery platform for numerous active compounds. The hydrogel platform, TRI-726, is capable of …See details»

MilanaPharm - Tech Stack, Apps, Patents & Trademarks

MilanaPharm is a privately held specialty pharmaceutical company built upon a proprietary drug delivery platform.See details»

J Mark Traylor - Member Board of Directors - MilanaPharm, LLC

President, Traylor-Porter Healthcare · Experience: MilanaPharm, LLC · Education: University of Alabama · Location: Opelika · 500+ connections on LinkedIn. View J Mark Traylor’s profile on...See details»

MilanaPharm CEO, Founder, Key Executive Team, Board of …

Explore {MilanaPharm's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»

Hammock Pharmaceuticals Announces the Licensing of Women's …

CHARLOTTE, N.C., Jan. 9, 2017 /PRNewswire/ -- Hammock Pharmaceuticals, Inc. today announced the execution of a license agreement with MilanaPharm/TriLogic Pharma for the …See details»

Chronic Wound Care Management and Research

Feb 17, 2023 · In this weeklong study, the new lidocaine gel was applied once on day 0 and patients recorded their perceived pain level for the next 7 days. Mean reported pain scores …See details»

Treatment Of Pain In Wounds With A Topical Long Acting …

Nov 1, 2019 · Mean reported pain scores and pain intensity difference (PID) were statistically significantly lower on days 1–4 compared to day 0 and days 5–7. This new lidocaine gel was …See details»

linkstock.net © 2022. All rights reserved